Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.30 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3985289 | 0.89 | GLRA1 (0.37) | ALDH1A1TSHRALOX15GLRA1SLC6A9 | |
| SCHEMBL2493116 | 0.87 | CA12 (0.41) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL9065819 | 0.86 | LMNA (0.44) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL621722 | 0.84 | CA12 (0.39) | ALDH1A1CA12CA1CA2CA9 | |
| SCHEMBL4281077 | 0.80 | CA12 (0.33) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL3504892 | 0.80 | ALDH1A1 (0.33) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL27397564 | 0.78 | CA12 (0.32) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL9243432 | 0.78 | CA12 (0.44) | ALDH1A1TSHRCA12CA1CA2 | |
| SCHEMBL6247927 | 0.77 | CAMK2A (0.38) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL6883197 | 0.77 | CA12 (0.35) | CA12CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115052932-A | Composition, method for preparing copolymer and end use of copolymer | 美国陶氏有机硅公司 | 2022-09-13 | — | — | CN | disclosed |
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20090018133-A1 | Novel Adamantane Derivatives | FORD RHONAN | 2009-01-15 | — | — | US | disclosed |
| US-20050090524-A1 | Novel adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-28 | — | — | US | disclosed |
| EP-1490341-A1 | NOVEL ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003080579-A1 | NOVEL ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234351-A1 | FUSED NITROGEN-COMPRISING HETEROCYCLIC COMPOUND | NR0B2, NR0B1, NR4A3 | ALDH1A1 3643/4885TSHR 519/4885CA12 2140/4885 |
| US-20090018133-A1 | Novel Adamantane Derivatives | ADRA1A, ADORA1, ADRA1D | ALDH1A1 117/4885TSHR 1280/4885CA12 3578/4885 |
| US-20050090524-A1 | Novel adamantane derivatives | ADRA1A, ADORA1, ADRA1D | ALDH1A1 91/4885TSHR 1959/4885CA12 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.